Cirrhotic patients in the ICU: prognostic markers and outcome.

Curr Opin Crit Care

Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.

Published: April 2013

Purpose Of Review: Give an update on the importance of prognostic scores at admission to the ICU for defining short-term outcome in critically ill cirrhotic patients. Highlight the correlation between the development of sepsis and/or organ failure and outcome.

Recent Findings: ICU mortality rate of cirrhotic patients admitted to the ICU ranges from 34 to 69%. Few improvements in the management of these patients occurred during the last decade. Definitive treatment relies mainly on the availability of transplant organs. ICU scores (mainly Sequential Organ Failure Assessment score) when performed at admission or within 2-4 days from admission are superior to liver specific scores (Model for End-Stage Liver Disease and Child-Pugh scores) to determine outcome. Cirrhotic patients with three or more organ failures have higher mortality then general ICU patients in the same condition. An attempt to define an entity called 'acute on chronic liver failure' that characterizes better those patients with worse outcomes according to the numbers of organ failures is currently undergoing.

Summary: Early referral of cirrhotic patients to ICU before the development of multiple extrahepatic organ failure is essential to improve outcome. Current scores should be used only for clinical trials and not to determine the potential futility or costs of an ICU admission.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCC.0b013e32835f0c17DOI Listing

Publication Analysis

Top Keywords

cirrhotic patients
20
organ failure
12
icu
8
patients icu
8
organ failures
8
patients
7
cirrhotic
5
scores
5
organ
5
icu prognostic
4

Similar Publications

Background: Patients with cirrhosis are susceptible to infections due to abnormalities in humoral and cell-mediated immunity. Fungal infections are associated with delayed diagnosis and high mortality rates, emphasizing the importance of performing fungal cultures and maintaining elevated levels of suspicion in this patient population.

Methods: This retrospective cohort study analyzes cirrhotic patients readmitted with bacterial and fungal infections and investigates outcomes, including in-hospital mortality and hospital resource utilization.

View Article and Find Full Text PDF

Introduction: Liver cirrhosis, a complex and progressive disease,imposes a significant global health burden, characterized by irreversible livertissue scarring and various life-threatening complications. Traditionallylinked to factors like chronic alcohol consumption and viral hepatitisinfections, the rising prevalence of obesity introduces a new dimension to itsetiology. As obesity rates continue to climb worldwide, the confluence of livercirrhosis and bariatric surgery has become an increasingly pertinent andclinically relevant topic of inquiry.

View Article and Find Full Text PDF

TERT de novo mutation-associated dyskeratosis congenita and porto-sinusoidal vascular disease: a case report.

J Med Case Rep

January 2025

Department of Hepatic Biliary Pancreatic Medicine, First Hospital of Jilin University, 1 Xinmin Avenue, Changchun, 130021, China.

Background: Dyskeratosis congenita is a rare genetic disease due to telomere biology disorder and characterized by heterogeneous clinical manifestations and severe complications. "Porto-sinusoidal vascular disease" has been recently proposed, according to new diagnostic criteria, to replace the term "idiopathic non-cirrhotic portal hypertension." TERT plays an important role in telomeric DNA repair and replication.

View Article and Find Full Text PDF

Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System.

Trends Cardiovasc Med

January 2025

Department of Cardiology, Euroclinic Hospital, Athens, Greece; First Department of Cardiology, Athens University School of Medicine, Athens, Greece. Electronic address:

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty-liver disease, is an important and rising health issue with a link with atherosclerotic cardiovascular (CV) disease (CVD), affecting ∼25-30% of the adults in the general population; in patients with diabetes, its prevalence culminates to ∼70%; its evolutive form, nonalcoholic steatohepatitis, is estimated to be the main cause of liver transplantation in the future. MASLD is a multisystem disease that affects, besides the liver, extra-hepatic organs and regulatory pathways; it raises the risk of type 2 diabetes mellitus (T2D), CVD, and chronic kidney disease; the disease may also progress to hepatocellular carcinoma. Its diagnosis requires hepatic steatosis and at least one cardiometabolic risk factor and the exclusion of both significant alcohol consumption and other competing causes of chronic liver disease.

View Article and Find Full Text PDF

Aim Of The Study: To assess the serum level of Mac-2 binding protein glycosylation isomer as a potential biomarker for hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) cirrhotic patients.

Material And Methods: Ninety patients were separated into two groups for the current research. Group I consisted of 45 patients with HCV that resulted in liver cirrhosis but no HCC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!